VHCP Management II as of March 31, 2018
Portfolio Holdings for VHCP Management II
VHCP Management II holds 17 positions in its portfolio as reported in the March 2018 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Avexis | 30.9 | $128M | 1.0M | 123.58 | |
| Endocyte | 9.4 | $39M | 4.3M | 9.09 | |
| Ascendis Pharma A S (ASND) | 9.2 | $38M | 586k | 65.40 | |
| Biohaven Pharmaceutical Holding | 8.6 | $36M | 1.4M | 25.76 | |
| Obseva Sa | 7.0 | $29M | 2.1M | 13.49 | |
| Argenx Se (ARGX) | 6.7 | $28M | 347k | 80.39 | |
| Anaptysbio Inc Common (ANAB) | 4.5 | $19M | 181k | 104.08 | |
| Dbv Technologies (DBVTF) | 4.4 | $18M | 616k | 29.42 | |
| Zogenix | 3.5 | $15M | 362k | 40.05 | |
| Catalyst Biosciences | 3.5 | $14M | 554k | 25.80 | |
| Menlo Therapeutics | 3.1 | $13M | 340k | 37.58 | |
| BioCryst Pharmaceuticals (BCRX) | 2.6 | $11M | 2.2M | 4.77 | |
| Bellerophon Therapeutics | 2.1 | $8.6M | 4.1M | 2.08 | |
| Momenta Pharmaceuticals | 1.9 | $7.7M | 425k | 18.15 | |
| Spero Therapeutics (SPRO) | 1.7 | $6.9M | 486k | 14.25 | |
| Ra Pharmaceuticals | 0.7 | $2.9M | 545k | 5.31 | |
| Savara (SVRA) | 0.3 | $1.1M | 120k | 9.20 |
